Patent portfolio with over 100 patents, issued and pending, protects expertise concentrating on a $100 billion market alternative
Firm growing potential breakthrough two-fold expertise that may doubtlessly detect problematic neural indicators and ablate nerves in a single easy process for ache administration and different indications
THE WOODLANDS, TX, April 16, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Firm”), a medical machine firm centered on advancing revolutionary applied sciences to revolutionize how illnesses involving the nervous system are identified and handled, in the present day introduced that the U.S. Patent and Trademark Workplace (USPTO) has issued U.S. patent 10,143,419 (‘419 patent) entitled “Methods and Strategies for Treating Most cancers and/or Augmenting Organ Perform.”
The issued patent is directed to expertise together with, however not restricted to, techniques, strategies and gadgets for interventionally treating cancerous tumors and most cancers associated ache. The Firm is initially advancing the event of its expertise to deal with pancreatic cancer-related ache.
Lori Bisson, Chief Govt Officer of Autonomix, commented, “The issuance of this U.S. patent represents a big milestone for the Firm and the continuing growth of our doubtlessly breakthrough expertise. We place a excessive precedence on safety of our novel expertise and have invested in constructing a deep patent portfolio of 15 patent households with over 100 patents, issued and pending. We’re dedicated to advancing the event of our expertise with the purpose of bringing nerve focused remedy to sufferers and consider this patent additional validates the potential of our expertise. Along with our preliminary concentrate on the profitable completion of our first in man examine for pancreatic most cancers ache, a multi-billion greenback market alternative, we’re investigating further makes use of for the expertise in different high-value indications with unmet wants.”
The Firm’s catheter-based sensing expertise is being developed to do two issues: sense neural indicators related to ache or illness and exactly goal these nerves for therapy. Autonomix believes this expertise is a greater various to the present approaches generally used in the present day, the place docs both depend on systemic medication like opioids that lose effectiveness and have undesirable unwanted effects or deal with suspected areas blindly in hopes of hitting the appropriate nerves, an method that’s usually inaccurate and may miss the goal and even trigger collateral harm to surrounding elements of the physique.
The Firm is initially growing its expertise to deal with pancreatic cancer-related ache. Present approaches, primarily counting on opioids or invasive ethanol injections, can present solely restricted reduction and will result in dangerous unwanted effects. For extra details about the Firm’s expertise, please go to autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical machine firm centered on advancing revolutionary applied sciences to revolutionize how illnesses involving the nervous system are identified and handled. The Firm’s first-in-class expertise platform features a catheter-based microchip sensing array that has the flexibility to detect and differentiate neural indicators with roughly 3,000 occasions better sensitivity than presently out there applied sciences. We consider it will allow, for the primary time ever, transvascular analysis and therapy of illnesses involving the peripheral nervous system nearly anyplace within the physique.
We’re initially growing our expertise for pancreatic most cancers ache, a situation that may trigger debilitating ache and desires an efficient resolution. Nevertheless, our expertise constitutes a platform with the potential to deal with dozens of indications, together with in cardiology, renal denervation and persistent ache administration throughout a large illness spectrum.
For extra info, go to autonomix.com and join with the Firm on X, LinkedIn, Instagram and Facebook.
Ahead Wanting Statements
Among the statements on this launch are “forward-looking statements,” which contain dangers and uncertainties. Ahead wanting statements on this press launch embody, with out limitation, the potential of the expertise to deal with hypertension and to finish its scientific examine in pancreatic most cancers ache. Such forward-looking statements might be recognized by way of phrases akin to ‘ought to,’ ‘could,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘tasks,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’
Though Autonomix Medical, Inc. (or Autonomix) believes that the expectations mirrored in these forward-looking statements are primarily based on affordable assumptions, there are a selection of dangers and uncertainties that might trigger precise outcomes to vary materially from such forward-looking statements. You might be urged to fastidiously evaluate and contemplate any cautionary statements and different disclosures, together with the statements made beneath the heading “Threat Components” and elsewhere within the providing round filed with the U.S. Securities and Trade Fee (“SEC”) on January 26, 2024. Ahead-looking statements converse solely as of the date of the doc by which they’re contained and Autonomix doesn’t undertake any responsibility to replace any forward-looking statements besides as could also be required by legislation.
Investor and Media Contact
JTC Crew, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com